bioAffinity to present new perspectives on CyPath Lung at CHEST 2026
bioAffinity aims to improve lung cancer risk stratification at CHEST 2026 with its noninvasive sputum-based CyPath Lung test, led by Chief Medical Officer Dr. Gordon Downie. The company also plans to discuss investigative research for asthma and COPD.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed